MATTHEW VINNACOMBE: Open Payments
NPI 1053780981 · MOOSIC, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$898 in 62 payments from 14 companies in 2025. Trend: 2023 $1,626 · 2024 $1,787 · 2025 $898
Food & beverage: $898
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $195 |
| ABBVIE INC. | 16 | $176 |
| E.R. Squibb & Sons, L.L.C. | 11 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $90 |
| Neurocrine BioSciences, Inc. | 3 | $50 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Alkermes, Inc. | 2 | $33 |
| Lundbeck LLC | 2 | $32 |
| Almatica Pharma LLC | 2 | $29 |
Products named: REXULTI, VRAYLAR, COBENFY, TRINTELLIX, INGREZZA, CAPLYTA, UZEDY, ARISTADA.
Industry payments across PA — which companies pay providers there.
